Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Particulate form
Reexamination Certificate
2002-04-17
2010-10-19
Tran, S. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Particulate form
C424S451000, C424S464000, C424S472000, C424S490000
Reexamination Certificate
active
07815940
ABSTRACT:
An oral pharmaceutical dosage form comprises pharmacologically effective amounts of an acid susceptible proton pump inhibitor or a salt thereof, an H2 receptor antagonist or a salt thereof and a pharmaceutically acceptable carrier. The dosage form is capable of raising gastric pH to above 4 within two hours after administration and to keep it at that level for at least 4 hours. Also disclosed is a method of manufacture of the dosage form, its use in treating dyspepsia and infection byHelicobacter pylori, and a method of treating disorders associated with gastric acid secretion.
REFERENCES:
patent: 4283408 (1981-08-01), Hirata et al.
patent: 5204118 (1993-04-01), Goldman et al.
patent: 5244670 (1993-09-01), Upson et al.
patent: 5651987 (1997-07-01), Fuisz
patent: 5840737 (1998-11-01), Phillips
patent: 6013680 (2000-01-01), Ogawa et al.
patent: 6077830 (2000-06-01), Vertesy et al.
patent: 6132768 (2000-10-01), Sachs et al.
patent: 6132771 (2000-10-01), Depui et al.
patent: 6183776 (2001-02-01), Depui et al.
patent: 6274173 (2001-08-01), Sachs et al.
patent: 6316469 (2001-11-01), Krishnan et al.
patent: 6489346 (2002-12-01), Phillips
patent: 6645988 (2003-11-01), Phillips
patent: 6699885 (2004-03-01), Phillips
patent: 6852739 (2005-02-01), Garvey et al.
patent: 6949264 (2005-09-01), McGrew et al.
patent: 2004/0171646 (2004-09-01), Phillips
patent: 2005/0054682 (2005-03-01), Phillips
patent: 19925710 (2000-12-01), None
patent: 0005129 (1979-10-01), None
patent: 0166287 (1986-01-01), None
patent: 0 338 861 (1989-10-01), None
patent: 2163747 (1986-03-01), None
patent: 2342292 (2000-04-01), None
patent: 2000-63280 (2000-02-01), None
patent: WO90/06925 (1990-06-01), None
patent: WO91/19711 (1991-12-01), None
patent: WO91/19712 (1991-12-01), None
patent: WO 93/11750 (1993-06-01), None
patent: WO94/27988 (1994-12-01), None
patent: WO 95/01780 (1995-01-01), None
patent: WO95/01977 (1995-01-01), None
patent: WO 95/22320 (1995-08-01), None
patent: WO 9522320 (1995-08-01), None
patent: WO 97/25066 (1997-07-01), None
patent: WO 9725065 (1997-07-01), None
patent: WO 9725066 (1997-07-01), None
patent: WO 98/40054 (1998-09-01), None
patent: WO 99/04773 (1999-02-01), None
patent: WO 99/04773 (1999-02-01), None
patent: WO 99/33448 (1999-07-01), None
patent: WO 00/09092 (2000-02-01), None
patent: WO00/78284 (2000-12-01), None
patent: WO2002/083132 (2002-10-01), None
patent: WO 97/25065 (2007-07-01), None
Peghini et al. “Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects”; Gastroenterology 1998, vol. 115:1335-1339.
Aliment Pharmacol Ther. vol. 13, 1999, M. Geschwantler et al.: “Famotidine versus omeprazole in combination with clarithromycin and metronidazole for eradication of Helicobacter pyroli- a randomized, controlled trial”, pp. 1063-1069, abstract, introduction, discussion.
G. Sachs, “Improving on PPI-based therapy of GORD”, Europen Journal of Gastroenterology & Hepatology, 13(suppl 1):S35-S41 (2001).
Andersson et al., “Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases”, Pharmacology & Therapeutics, 108:294-307 (2005).
Cheng, “Combined Use of Proton Pump Inhibitors and Histamine-H2 Receptor Antagonists for GERD: What is the rationale?”Canadian Phar-maceutical Journal, Sep. 2002, pp. 27-29,45.
Hirschowitz et al., “Pharmacological Aspects of Acid Secretion”Digestive Diseases and Sciences, Feb. 1995; pp. 3S-23S.
Hunt et al, “Optimizing Acid Suppression for Treatment of Acid-Related Diseases”Digestive Diseases and Sciences, 1995, vol. 40:24S-49S.
Nwokolo et al., “Tolerance During 29 Days of Conventional Dosing with Cimetidine, Nizatidine, Famotidine or Ranitidin”Aliment. Pharmacol. Therap., 1990, pp. 29-45.
Richardson et al., “Proton Pump Inhibitors, Pharmacology and Rationale for Use in Gastrointestinal Disorders”Drugs, Sep. 1998, vol. 56, No. 3, pp. 307-335.
Sachs et al., The Pharmacology of The Gastric Acid Pump: The H+,K+ ATPase,Annu. Rev. Pharmacol. Toxicol, 1995; pp. 277-305.
Sachs, George, “Proton Pump Inhibitors and Acid-Related Diseases”Pharmacotherapy (Reviews of Therapeutics, 1997; pp. 22-37.
Shin et al., “Structural Aspects of the Gastric H,K ATPase”Annals New York Academy of Sciences, 1997; pp. 65-76.
DeGraef et al., “Influence of the Stimulation State of the Parietal Cells on the Inhibitory Effect of Omeprazole on Gastric Acid Secretion in Dogs”,Gastroenterology, Aug. 1986; vol. 91, No. 2, pp. 333-337.
Hunt, et al., “Optimizing Acid Suppression for Treatment of Acid-Related Diseases”Digestive Diseases and Sciences, Feb. 1995; pp. 24S-49S.
Nwokolo et al., “Tolerance During 29 days of Conventional Dosing with Dimetidine, Nizatidine, Famotidine or Ranitidine”Aliment. Pharmacol. Therap, 1990, pp. 29-45.
Hirschowitz et al., “Pharmacological Aspects of Acid Secretion”Digestive Diseases and Sciences, Feb. 1995; pp. 3S-23S.
Sachs, G., “Proton Pump Inhibitors and Acid-Related Diseases”Reviews of Therapeutics, (Pharmacotherapy), Feb. 1997, pp. 22-37.
Richardson et al., “Proton Pump Inhibitors, Pharmacology and Rationale for Use in Gastrointestinal Disorders”Drugs, Sep. 1988, pp. 307-335.
Shin et al., “Structural Aspects of the Gastric H,K ATPase”Annals of the New York Academy of Sciences1997, pp. 65-76.
Sachs et al., “The Pharmacology of the Gastric Acid Pump: The H+K+ ATPase”Annual Review of Pharmacology and Toxicology, 1995; pp. 277-305.
Sachs, “Improving on PPI-Based Therapy of GORD”,European Journal of Gastroenterology&Hepatology, 2001, pp. S35-S41.
Aulton, “Pharaceutics, the Science of Dosage Form Design”, , 1988; pp. 289-305.
Huang et al., “pH, Healing and Symptoms in Patients with GERD”,The Yale Journal of Biology and Medicine, Jun. 1999; pp. 182-194.
Shin et al., “Structural Aspects of the Gastric H,K ATPase”Annals New York Academy of Sciences, 1997; pp. 65-76.
Curriculum Vitae (CV) of Nimish Vakil, M.D., FACP, FACG (Exhibit 1 to Vakil Declaration).
Dent, Armstrong, Delany, Moayyedi, Talley, Vakil, “Symptom Evaluation in Reflux Disease: Workshop Background, Processes, Terminology, Recommendations, and Discussion Outputs,” Gut 2004; 53 (Suppl IV):iv1-iv24) (Attachment 12 to Vakil Declaration).
Vakil et al, “The Montreal Definition and Classification of Gastroesophageal Reflux Disease: A Global Evidence-Based Consensus,”Am J Gastroenterology2006: 101:1900-1920 (Attachment 13 to Vakil Declaration).
Flock, Jones, and Vakil, “Approach to Gastroesophageal Reflux Disease in Primary Care,”Can Fam Physician2008; 54:701-5) (Attachment 14 to Vakil Declaration).
American Journal of Gastroenterology, Vol. 96, No. 2, 2001. pp. 303-314, accepted for publication Oct. 6, 2000) (Attachment 2 to Vakil Declaration).
Title 21 U.S.C. § 331.11 (Food and Drugs) (1974) (Attachment 3 to Vakil Declaration).
N. Vakil, “Review Article: Cost-Effectiveness of Different GERD Management Strategies,”Aliment Pharmacol Ther2002; 16 (Suppl. 4): 79-82, p. 80) (Attachment 4 to Vakil Declaration).
Vakil, “Novel Methods of Using Proton-Pump Inhibitors,”Gasteroenterol Clin N Am31 (2002) S85-88, 87-88) (Attachment 5 to Vakil Declaration).
Vakil et al., “The Effect of Over-the-Counter Rantidine 75 mg on Night-Time Heartburn in Patients With Erosive Oesophagitis on Daily Proton Pump Inhibitor Maintenance Therapy,”Aliment Pharacol Ther23 (2006), 649-653) (Attachment 11 to Vakil Declaration).
M. Michael Wolfe, M.D. (Professor, Boston University School of Medicine) and George Sachs, M.D. (Professor, UCLA School of Medicine), “Acid Suppression: Optimizing Therapy for Gastroduodenal Ulcer Healing, Gastroesophageal Reflux Disease, and Stress-Related Erosive Syndrome,”Gastroenterology2000; 118:S9-S31 (Attach
Orexo AB
Ryan Kromholz & Manion S.C.
Tran S.
LandOfFree
Gastric acid secretion inhibiting composition does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Gastric acid secretion inhibiting composition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Gastric acid secretion inhibiting composition will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4237831